t(9;22)(q34;q11) BCR/ABL1 in CML

2000-10-01   Ali G Turhan  

1.Translational Research - Cell Therapy, Laboratory, INSTITUT GUSTAVE ROUSSY, INSERM U. 362, 1 - 39, rue Camille Desmoulins, 94805 VILLEJUIF CEDEX - FRANCE
2.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Clinics and Pathology

Disease

CML: all CML have a t(9;22), at least at the molecular level (seebelow); but not all t(9;22) are found in CML, as already noted

Phenotype stem cell origin

Evidence exists for the involvement of the most primitive and quiescent hematopoietic stem cell compartiment (CD34+/CD38-, Thy1+): t(9;22) is found in myeloid progenitor and in B-lymphocytes progenitors, but, involvement of the T-cell lineage is extremely rare

Epidemiology

annual incidence: 10/106 (from 1/106 in childhood to 30/106after 60 yrs); median age: 30-60 yrs; sex ratio: 1.2M/1F

Clinics

splenomegaly; chronic phase (lasts about 3 yrs) with maintained cells normal activities, followed by accelerated phase(s) (blasts still < 15%), and blast crisis (BC-CML) with blast cells > 30%; blood data: WBC: 100 X 109/l and more during chronic phase, with basophilia; a few blasts; thrombocytosis may be present; low leucocyte alkaline phosphatases; typical acute leukaemia (AL) blood data at the time of myeloid or lymphoid -type blast crisis

Cytology

hyperplastic bone marrow; granulocytes proliferation, with maturation; followed by typical AL cytology (see t(9;22)(q34;q11)/AML, and t(9;22)(q34;q11)/ALL)

Treatment

aIFN therapy or allogeneic bone marrow transplantation (BMT), donor leukocytes infusions

Prognosis

median survival: 4 yrs with conventional therapy (hydroxyurea, busulfan), 6 yrs with aIFN therapy; allogeneic bone marrow transplantation may cure the patient; otherwise, the best treatment to date associates interferon a, hydroxyurea and cytarabine

Cytogenetics

Cytogenetics morphological

the chromosomal anomaly persists during remission, in contrast with acute leukemia (AL) cases

Cytogenetics molecular

is a useful tool for diagnostic ascertainment in the case of a masked Philadelphia chromosome, where chromosomes 9 and 22 all appear to be normal, but where cryptic insertion of 3 ABL within a chromosome 22 can be demonstrated

Additional anomalies

1. may be present at diagnosis (in 10%, possibly with unfavourable significance), or may appear during course of the disease, they do not indicate the imminence of a blast crisis, although these additional anomalies also emerge frequently at the time of acute transformation;
2. these are: +der(22), +8, i(17q), +19, most often, but also: +21, -Y, -7, -17, +17; acute transformation can also be accompanied with t(3;21) (q26;q22) (1% of cases); near haploidy can occur; of note, although rare, is the occurrence of chromosome anomalies which are typical of a given BC phenotype (e.g. t(15;17) in a promyelocytic transformation, dic(9;12) in a CD10+ lymphoblastic BC ...); +8, +19, +21, and i(17q) occur more often in myeloid -rather than lymphoid- blast crises

Variants

t(9;22;V) and apparent t(V;22) or t(9;V), where V is a variable chromosome, are found in 5-10% of cases; however, 9q34-3ABL always joins 22q11-5BCR in true CML; the third chromosome and breakpoint is, at times, not random. In a way, masked Philadelphia chromosomes (see above) are also variants.
Atlas Image
835J22 + 1132H12 and 72M14 Cohybridization of (835J22 + 1132H12; ABL) and 72M14 (BCR) on a CML patient carrying the t(9;22) translocation. Note the splitting of (835J22 + 1132H12) (red signal) and the colocalization on Ph chromosome (Ph) -Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics
Atlas Image
Cryptic insertion of BCR within chromosome 9. FISH using the Vysis LSI BCR/ABL Dual Color, Dual Fusion Translocation Probe - Courtesy Karolien Beel, Geneviu00e8ve Ameye and Lucienne Michaux, CME, UZ Leuven

Genes Involved and Proteins

Gene name
ABL1 (v-abl Abelson murine leukemia viral oncogene homolog 1)
Location
9q34.12
Dna rna description
alternate splicing (1a and 1b) in 5
Protein description
giving rise to 2 proteins of 145 kDa; contains SH (SRC homology) domains; N-term SH3 and SH2 - SH1 (tyrosine kinase) - DNA binding motif - actin binding domain C-term; widely expressed; localisation is mainly nuclear; inhibits cell growth
Gene name
BCR (Breakpoint cluster region)
Location
22q11.23
Dna rna description
various splicings
Protein description
main form: 160 KDa; N-term Serine-Treonine kinase domain, SH2 binding, and C-term domain which functions as a GTPase activating protein for p21rac; widely expressed; cytoplasmic localisation; protein kinase; probable role in signal transduction

Result of the Chromosomal Anomaly

Description

1. the crucial event lies on der(22), id est 5 BCR/3 ABL hybrid gene is pathogenic, while ABL/BCR may or may not be expressed;
2. breakpoint in ABL is variable over a region of 200 kb, often between the two alternative exons 1b and 1a, sometimes 5 of 1b, or 3 of 1a, but always 5 of exon 2;
3. breakpoint in BCR is in a narrow region, therefore called M-bcr (for major breakpoint cluster region), a cluster of 5.8 kb, between exons 12 and 16, also called b1 to b5 of M-bcr; most breakpoints being either between b2 and b3, or between b3 and b4

Transcript

8.5 kb mRNA, resulting in a 210 KDa chimeric protein

Detection protocole

RT-PCR for minimal residual disease detection

Description

P210 with the first 902 or 927 amino acids from BCR; BCR/ABL has a cytoplasmic localization, in contrast with ABL, mostly nuclear. It is now clearly established that BCR-ABL is the oncogene responsible for the occurrence of CML . The hybrid protein has an increased protein kinase activity compared to ABL: 3BP1 (binding protein) binds normal ABL on SH3 domain, which prevents SH1 activation; with BCR/ABL, the first (N-terminal) exon of BCR binds to SH2, hidding SH3 which, as a consequence, cannot be bound to 3BP1; thereof, SH1 is activated

Oncogenesis

  • A- Major molecular pathways activated by BCR-ABL.
  • BCR/ABL activates RAS signaling through the GRB2 adaptor molecule which interacts specifically with the Y177 of BCR..
  • PI3-K (phosphatidyl inositol 3 kinase) pathway is also activated with secondary activation of the AKT/PKB pathway.
  • Integrity of transcription machinery induced by MYC is necessary for the transforming action of BCR-ABL.
  • More recently, activation of STAT (Signal transducers and activators of transcription) molecules has been described as a major molecular signaling event induced by BCR-ABL, with activation of essentially STAT5, 1, and 6.
  • Activation of the molecules of the focal adhesion complex (PAXILLIN, FAK) by BCR-ABL requires the role of the adaptor molecule CRK-L.
  • BCR-ABL activates negative regulatory molecules such as PTP1B and Abi-1 and their inactivation could be associated with progression into blast crisis.
  • B- Correlations between molecular pathways and leukemic phenotype observed in primary CML cells or in BCR-ABL-transduced cells are currently limited.
  • BCR-ABL has anti-apoptotic activity (PI63K/Akt/STAT5) .
  • BCR/ABL induces cell adhesive and migratory abnormalities in vitro in the presence of fibronection or in transwell assays (Abnormal integrin signaling/FAK/CRK-L/Abnormal response to chemokine SDF-1).
  • BCR-ABL induces a dose-effect relationship in CML cells with increased BCR-ABL mRNA during progression into blast crisis, with induction of genetic instability.
  • Molecular events associated with blast crisis: P53 mutation, methylation of ABL promoter, telomere shortening, Abi-1 inactivation.
  • Highly cited references

    Pubmed IDYearTitleCitations
    350571082022BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.188
    385422792024Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.131
    420513762026BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβ.113
    371296982023Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.101
    373371052023Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia.91
    385509482023Targeting BCR-ABL1-positive leukaemias: a review article.88
    413734452025Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation.85
    386532452024Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.83
    417644062026BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs.81
    376291882023Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms.80
    358096442022Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.73
    318015822019Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.72
    330540452020BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy.69
    383972212024Frequencies of BCR::ABL1 Transcripts in Patients with Chronic Myeloid Leukemia: A Meta-Analysis.67
    373974962023BCR-ABL1-positive acute lymphoblastic leukemia following successful treatment of acute promyelocytic leukemia: case report.61
    331720632020Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR.55
    355514632022BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.51
    287073212017Expansion of BCR/ABL1(+) cells requires PAK2 but not PAK1.44
    374008422023BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases.41
    286988602017Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach.41
    392140962024Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.34
    353610362022Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.23
    344858062021Report of Canonical BCR-ABL1 Fusion in Glioblastoma.21
    338145002021BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy.20
    301259552018Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.19
    365182372022BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia.18
    289830612018BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.16
    387501372024Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.15
    376210712023Co-existence of RUNX1-RUNX1T1 and BCR-ABL1 in acute myeloid leukemia: a case report.15
    388796102024The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.15
    390854022024Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.15
    363486352022Detection of NUP214-ABL1 translocation using BCR-ABL1 dual color FISH probes in T-cell acute lymphoblastic leukemia-an illustrative report and review of literature.15
    410530782025BCR::ABL1-positive acute lymphoblastic leukemia as a high-risk feature of central nervous system relapse after allogeneic hematopoietic cell transplantation.14
    374074562024High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.14
    347586082022Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia.13
    356992772022Initial Rate of BCR::ABL1 Decline for Response Prediction in Chronic Myeloid Leukemia.13
    388796112024Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients.13
    351127162022BCR::ABL1 transcripts and clinical outcome - interrogating the technique.11
    411635762026CML-like biology: BCR::ABL1 and beyond.10
    368434082023Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy.9
    295522782018Cytogenetic alterations in CML: not all created equal.8
    222103262012The other Achilles' heel of BCR-ABL1.6
    276308612016No Benefit of BCR-ABL1 Screening in Polycythemia.5
    322112872020Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia.5
    399321242025BCR::ABL1-Positive Acute Myeloid Leukemia.2
    386048192024Chronic myeloid leukaemia: Biology and therapy.0
    329082502020Declaration of Bcr-Abl1 independence.0
    268693042016BCR-ABL1 mutation ≠ ponatinib resistance.0
    303704782018Chronic Myeloid Leukemia: Beyond BCR-ABL1.0
    283815352017Double trouble for CML.0
    305617552019BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?0
    268430452016Digital PCR: Principles and Applications.0
    322706992020Basic knowledge on BCR-ABL1-positive extracellular vesicles.0
    330389882020CML - Not only BCR-ABL1 matters.0
    366369582023BCR::ABL1-positive chronic myeloid leukaemia with CALR mutation.0
    375483332023BCR-ABL1 co-occurring with CBFA2T3-GLIS2 and RAM immunophenotype in a non-Down syndrome infant with acute megakaryoblastic leukemia.0
    309910252019γ-Catenin-Dependent Signals Maintain BCR-ABL1(+) B Cell Acute Lymphoblastic Leukemia.0
    348186442022BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.0
    241318882014Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.0
    322001892020Novel therapeutic approaches in chronic myeloid leukemia.0
    393037282024Triplet therapy for advanced BCR::ABL1 positive myeloid leukaemias.0
    310699762019BCR-ABL1-like B-lymphoblastic leukemia/lymphoma: Review of the entity and detection methodologies.0
    374494652023Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?0
    346088292021Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.0
    340380342021Suspected chronic myeloid leukemia-like BCR-ABL1-positive acute lymphoblastic leukemia.0
    366529972023Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.0
    369588192023BCR::ABL1 screening is not indicated in patients with splenomegaly without neutrophilia and/or basophilia.0
    373023522023Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.0
    344964602022BCR::ABL1-positive histiocytic sarcoma of the small intestine in a patient with chronic myeloid leukaemia.0
    352670032022Pseudo-Chédiak-Higashi inclusions in BCR::ABL1-like B-lymphoblastic leukemia with IGH::EPOR rearrangement.0
    388605932024Atypical BCR-ABL1 transcript in mixed phenotype acute leukemia with bone marrow necrosis.0
    282220162017A review of the challenge in measuring and standardizing BCR-ABL1.0
    355624922022Subclonal acquisition of a BCR::ABL1 fusion in a chronic myelomonocytic leukemia.0
    387696892024BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.0
    379690542024BCR::ABL1 fusion gene positive de novo acute myeloid leukemia with coexistence of NRAS mutation and presented with a peculiar CD58 positive immunophenotype.0
    190021922008BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.0
    378719002024IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.0
    262080402016BCR-ABL1 b3a2 and b2a2 transcripts in chronic myeloid leukemia: does it matter?0
    347257112022Acute Promyelocytic Leukemia with a BCR-ABL1 Rearrangement in a Minor Clone.0
    315950382020In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent.0
    361567252022[BCR-ABL1 negative chronic myeloid leukemia: report of two cases].0
    393169902024Strategies to overcome splicing variants interference in mutational testing for BCR::ABL1 KD.0
    350210692022Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.0
    258955472015BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?0
    246275182014Refining prognosis in BCR-ABL1-positive ALL.0
    309387692019BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.0
    375303562023Identification of rare atypical BCR-ABL1 transcript: A case report.0
    410340522025[Mechanisms of resistance to the allosteric BCR::ABL1 inhibitor asciminib].0
    286630312017Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology.0
    255730332015Managing children with chronic myeloid leukaemia--response to Baccarani.0
    295085362018Chronic myeloid leukemia, BCR-ABL1-positive with CALR and MPL mutations.0
    266378442015Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.0
    353895072022Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1.0
    332840422021Development of BCR-ABL1-positive ɤδ T-cell leukemia after treatment for thymoma type B1.0
    345855202022Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization?0
    375877722023One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission.0
    310363152019BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?0
    374527892023Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.0
    281645282016Screening for BCR-ABL1 in Patients with an Isolated Eosinophilia.0
    322370842020Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia.0

    Bibliography

    No bibliography items were found for this article.

    Summary

    Note

    Although the same hybrid genes issued from ABL and BCR are the hallmark of the t(9;22) translocation, this translocation may be seen in the following diseases: chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL), and will therefore be described in the 3 different situations: t(9;22)(q34;q11) in CML, t(9;22)(q34;q11) in ALL, t(9;22)(q34;q11) in AMLt(9;22)(q34;q11) in CML is herein described
    Atlas Image
    t(9;22)(q34;q11) G- banding (left) - Courtesy Jean-Luc Lai and Alain Vanderhaegen (3 top) and Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap, UW Cytogenetic Services (2 bottom); R-banding (right) top: Editor; 2 others Courtesy Jean-Luc Lai and Alain Vanderhaegen); diagram and breakpoints (Editor).

    Citation

    Ali G Turhan

    t(9;22)(q34;q11) BCR/ABL1 in CML

    Atlas Genet Cytogenet Oncol Haematol. 2000-10-01

    Online version: http://atlasgeneticsoncology.org/haematological/1022/t(9;22)(q34;q11)-bcr-abl1-in-cml

    Historical Card

    1997-12-01 t(9;22)(q34;q11) BCR/ABL1 in CML by  Jean-Loup Huret,Jean-Loup Huret 

    Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France